Coronavirus Disease 2019: An Overview of the Complications and Management

Huimin Shao, Hany Sadek Ayoub Ghaly, P. Varamini
{"title":"Coronavirus Disease 2019: An Overview of the Complications and Management","authors":"Huimin Shao, Hany Sadek Ayoub Ghaly, P. Varamini","doi":"10.36922/ITPS.V4I1.1037","DOIUrl":null,"url":null,"abstract":"The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Since the first report of COVID-19 emerging in Wuhan, China, authorities in 216 countries and territories have reported about 47.3 million COVID-19 cases and 1.2 million deaths. The WHO guidelines for the management of COVID-19 are very limited to recommendations for managing symptoms and advice on careful management of pediatric patients, pregnant women, and patients with underlying comorbidities. There is no approved treatment for COVID-19 and guidelines vary between countries. In this review, first, a brief overview is provided on the basic knowledge about the virus, clinical features of the disease, and different diagnostic methods. Then, the relationship between COVID-19, various body systems, and other complications is discussed. Finallly, different management strategies are discussed, including those drawn on computational chemistry analyses, pre-clinical investigations, and clinical trials which involve pharmacological and non-pharmacological interventions. In conclusion, despite the recent approval of different vaccine candidates, more virological characteristics of SARS-CoV-2 are required to be explored, which may result in the discovery of more potential therapeutic targets leading to safer and more effective treatment to COVID-19.","PeriodicalId":13673,"journal":{"name":"INNOSC Theranostics and Pharmacological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INNOSC Theranostics and Pharmacological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36922/ITPS.V4I1.1037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Since the first report of COVID-19 emerging in Wuhan, China, authorities in 216 countries and territories have reported about 47.3 million COVID-19 cases and 1.2 million deaths. The WHO guidelines for the management of COVID-19 are very limited to recommendations for managing symptoms and advice on careful management of pediatric patients, pregnant women, and patients with underlying comorbidities. There is no approved treatment for COVID-19 and guidelines vary between countries. In this review, first, a brief overview is provided on the basic knowledge about the virus, clinical features of the disease, and different diagnostic methods. Then, the relationship between COVID-19, various body systems, and other complications is discussed. Finallly, different management strategies are discussed, including those drawn on computational chemistry analyses, pre-clinical investigations, and clinical trials which involve pharmacological and non-pharmacological interventions. In conclusion, despite the recent approval of different vaccine candidates, more virological characteristics of SARS-CoV-2 are required to be explored, which may result in the discovery of more potential therapeutic targets leading to safer and more effective treatment to COVID-19.
2019冠状病毒病:并发症及治疗概述
严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)是2019冠状病毒病(COVID-19)的病原体。自中国武汉首次报告COVID-19以来,216个国家和地区的当局报告了约4730万例COVID-19病例和120万例死亡。世卫组织COVID-19管理指南非常局限于对症状管理的建议以及对儿科患者、孕妇和有潜在合并症的患者进行仔细管理的建议。目前还没有批准的COVID-19治疗方法,各国的指南也各不相同。本文首先对该病毒的基本知识、临床特点及不同的诊断方法作一综述。然后,讨论了COVID-19与各种身体系统以及其他并发症之间的关系。最后,讨论了不同的管理策略,包括计算化学分析、临床前调查和涉及药物和非药物干预的临床试验。总之,尽管最近批准了不同的候选疫苗,但需要探索SARS-CoV-2的更多病毒学特征,这可能导致发现更多潜在的治疗靶点,从而更安全,更有效地治疗COVID-19。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信